

Applicants : Ron S. Israeli, et al.  
Serial No. : NOT YET KNOWN  
Filed : HERewith  
Page 11

prostatic tumor cells to kill those cells. PSM specific substrates may also be used in the treatment of benign prostatic hyperplasia.--

In the claims:

Please amend as follows:

Please cancel claims 1-23 without prejudice or disclaimer.

Please add the following new claims to the application:

--24. (New) A method comprising administering an inhibitor of the neurocarboxypeptidase activity of prostate specific membrane antigen so as to inhibit release of glutamate by N-acetylaspartylglutamic acid (NAAG) hydrolysis.--

--25. (New) The method of claim 24, wherein the inhibitor is MTXglu<sub>3</sub>, pteglu<sub>5</sub> or pABAglu<sub>5</sub>.

#### REMARKS

In the present Preliminary Amendment, claims 1-23 of the application are cancelled without prejudice or disclaimer, and replaced by new claims 24-25.

Support for these new claims is found, inter alia, in the specification as follows: Claim 24: page 92, lines 22-30 and page 102, lines 29-36, and Claim 25: page 102, lines 34-36.

These new claims, 24-25, therefore raise no issue of new matter and it is respectfully requested that they be entered into the file of the application.